Ganga Pharmaceuticals Limited (BOM:539680)
India · Delayed Price · Currency is INR 13.97
+2.17 (18.39%)
At close: Jan 22, 2026
Ganga Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 26.93 | 26.37 | 27.36 | 25.86 | 24.89 | 23.74 | Upgrade |
Other Revenue | - | - | -0 | - | - | - | Upgrade |
| 26.93 | 26.37 | 27.36 | 25.86 | 24.89 | 23.74 | Upgrade | |
Revenue Growth (YoY) | -1.29% | -3.60% | 5.78% | 3.91% | 4.83% | -22.88% | Upgrade |
Cost of Revenue | 12.27 | 12.19 | 12.51 | 12.49 | 12.92 | 12.44 | Upgrade |
Gross Profit | 14.66 | 14.18 | 14.85 | 13.38 | 11.97 | 11.31 | Upgrade |
Selling, General & Admin | 5.5 | 5.92 | 5.91 | 5.21 | 5.12 | 5.15 | Upgrade |
Other Operating Expenses | 9.42 | 9.42 | 8.37 | 8.13 | 6.43 | 5.84 | Upgrade |
Operating Expenses | 15.4 | 15.81 | 14.77 | 13.89 | 12.1 | 11.53 | Upgrade |
Operating Income | -0.75 | -1.63 | 0.08 | -0.51 | -0.13 | -0.23 | Upgrade |
Interest Expense | -1.46 | -1.69 | -1.81 | -1.87 | -1.9 | -2.18 | Upgrade |
Interest & Investment Income | 2.48 | 2.48 | 2.39 | 2.98 | 2.59 | 2.53 | Upgrade |
Other Non Operating Income (Expenses) | -1.55 | -0.1 | -0.04 | -0.07 | -0.04 | 0.25 | Upgrade |
EBT Excluding Unusual Items | -1.27 | -0.93 | 0.63 | 0.53 | 0.51 | 0.37 | Upgrade |
Gain (Loss) on Sale of Assets | 1.88 | 1.88 | - | - | - | - | Upgrade |
Pretax Income | 0.61 | 0.95 | 0.63 | 0.53 | 0.51 | 0.37 | Upgrade |
Income Tax Expense | -0.19 | 0.16 | 0.17 | 0.14 | 0.13 | 0.17 | Upgrade |
Net Income | 0.8 | 0.79 | 0.47 | 0.39 | 0.38 | 0.2 | Upgrade |
Net Income to Common | 0.8 | 0.79 | 0.47 | 0.39 | 0.38 | 0.2 | Upgrade |
Net Income Growth | 46.39% | 69.52% | 18.60% | 3.74% | 86.16% | -89.22% | Upgrade |
Shares Outstanding (Basic) | 6 | 5 | 5 | 4 | 4 | 4 | Upgrade |
Shares Outstanding (Diluted) | 7 | 7 | 7 | 4 | 4 | 4 | Upgrade |
Shares Change (YoY) | 4.46% | - | 62.79% | - | - | - | Upgrade |
EPS (Basic) | 0.14 | 0.16 | 0.10 | 0.10 | 0.09 | 0.05 | Upgrade |
EPS (Diluted) | 0.11 | 0.12 | 0.07 | 0.10 | 0.09 | 0.05 | Upgrade |
EPS Growth | 41.58% | 71.43% | -27.67% | 7.53% | 80.00% | -89.13% | Upgrade |
Free Cash Flow | -9.12 | -6.76 | -12.86 | -0.55 | -2.25 | -1.92 | Upgrade |
Free Cash Flow Per Share | -1.25 | -1.02 | -1.95 | -0.14 | -0.56 | -0.47 | Upgrade |
Gross Margin | 54.43% | 53.78% | 54.29% | 51.73% | 48.10% | 47.61% | Upgrade |
Operating Margin | -2.77% | -6.17% | 0.31% | -1.99% | -0.51% | -0.95% | Upgrade |
Profit Margin | 2.96% | 3.00% | 1.70% | 1.52% | 1.52% | 0.86% | Upgrade |
Free Cash Flow Margin | -33.85% | -25.63% | -47.02% | -2.11% | -9.06% | -8.10% | Upgrade |
EBITDA | -0.27 | -1.16 | 0.58 | 0.05 | 0.42 | 0.31 | Upgrade |
EBITDA Margin | -0.99% | -4.41% | 2.11% | 0.18% | 1.69% | 1.31% | Upgrade |
D&A For EBITDA | 0.48 | 0.47 | 0.49 | 0.56 | 0.55 | 0.54 | Upgrade |
EBIT | -0.75 | -1.63 | 0.08 | -0.51 | -0.13 | -0.23 | Upgrade |
EBIT Margin | -2.77% | -6.17% | 0.31% | -1.99% | -0.51% | -0.95% | Upgrade |
Effective Tax Rate | - | 16.55% | 26.33% | 26.01% | 26.00% | 45.58% | Upgrade |
Revenue as Reported | 29.84 | 30.73 | 29.75 | 28.85 | 27.48 | 26.29 | Upgrade |
Advertising Expenses | - | 0.15 | 0.11 | 0.1 | 0.13 | 0.22 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.